Dear Reader,
Elon Musk’s “AI Everywhere” project isn’t inside Tesla—it’s a private venture with a global network of 150+ facilities embedding autonomous AI into devices everywhere.
Musk believes this could propel Tesla to become the most valuable company ever, worth more than Apple, Microsoft, Nvidia, Amazon, and Google combined.
Private ventures like this are usually locked for elites, but I’ve found a legitimate brokerage backdoor—under $100, no special requirements, just a regular account.
Musk’s history proves he turns underdogs into giants:
- PayPal → Peter Thiel turned $1,700 into $55 million.
- SpaceX → valuation up 349,900% ($1,000 now worth over $3.4 million).
- Tesla → 22,000%+ since IPO ($1,000 to over $220,000).
- xAI → $0 to $230 billion in under two years.
This private play follows the same playbook—using Tesla’s proven autonomous AI “copy-pasted” across the world.
Watch my full video—I explain the story and give you 3 steps to profit, including how to claim that backdoor stake before the summer regulatory shift.
Here’s to the future,
Matt McCall
P.S. Ignore this and you could miss the biggest Musk-driven opportunity since Tesla’s early days.
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
Written by Jordan Chussler. Date Posted: 3/10/2026.
Key Points
- Hims & Hers has shifted from offering controversial compounded GLP-1s to a formal agreement with Novo Nordisk, allowing the platform to distribute FDA-approved Ozempic and Wegovy.
- Following the announcement, HIMS shares surged nearly 46%, helping the stock recover from a 59% drop earlier in the year caused by previous legal friction with Novo Nordisk.
- Analysts have upgraded the stock, citing the partnership as a major growth catalyst; despite a year-to-date loss, earnings are projected to grow by over 79% next year.
- Special Report: Elon's "Hidden" Company
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares surge following an agreement with GLP-1 maker Novo Nordisk (NYSE: NVO)—the same company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9.
After pulling its compounded semaglutide product modeled after Novo Nordisk's weight-loss drugs Wegovy and Ozempic, Hims & Hers announced in a press release that the two firms have entered a strategic partnership to make Novo Nordisk's obesity drugs available through the telehealth platform.
MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon (Ad)
Elon's Next Move Could Be His Greatest Yet
He revived EVs, revolutionized space, and built the biggest satellite network.
But this AI tech could go down in history as the crown jewel of Elon's career.
Nvidia CEO Jensen Huang says, "What Elon and his team has achieved is singular. It's never been done before."
Get the full story here.Since the announcement, HIMS has gained nearly 46% and received analyst upgrades as Wall Street turns more bullish on the direct-to-consumer prescription drug provider.
A Strategic Shift From Compounded GLP-1 to FDA-Approved Drugs
Amid surging demand and shortages for weight-loss drugs, compounded GLP-1 alternatives emerged to fill the void. However, compounded GLP-1 drugs do not have U.S. Food and Drug Administration (FDA) approval.
Although these alternatives expanded access and used similar active ingredients (for example, semaglutide and tirzepatide, the latter marketed as Mounjaro and Zepbound), their lack of FDA approval meant they did not undergo formal quality and efficacy reviews. That created risks such as incorrect dosages, improper storage, and other safety concerns.
According to Hims & Hers's press release, as part of the company's shift away from compounded GLP-1 offerings, "existing patients will have the opportunity to transition to FDA-approved medicines."
Specifically, "Hims & Hers has entered into an agreement with Novo Nordisk that will bring Ozempic (semaglutide) 0.5 mg, 1 mg, and 2 mg injections and Wegovy (semaglutide) pills and injections to the platform later this month, including 1.7 mg or 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, and 25 mg tablets."
Co-founder and CEO Andrew Dudum said the deal should create "tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications." He added that the "collaboration reflects what's possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations."
Shares of HIMS Are Still Under Pressure, but the Future Looks Promising
The recent announcement and the sizable bump in the stock's price were welcomed by shareholders who have endured Hims & Hers' volatility over the past year. Even after the Novo Nordisk–related sell-off in February, many analysts remained optimistic, with some 12-month price targets implying as much as 150% potential upside.
Even with the March 9 surge, HIMS shares are still down nearly 33% over the last 12 months. Fundamentally, however, Hims & Hers appears well-positioned to sustain growth.
When the company reported full-year and Q4 2025 earnings on Feb. 23, it posted an earnings-per-share (EPS) beat but a slight revenue miss. EPS of $0.08 topped analyst expectations of $0.02, while revenue of $617.82 million came in just under forecasts of $619.48 million.
It was the company's first EPS beat since the first quarter of last year. Importantly, the financial metrics showed steady, sustainable revenue growth, with a three-year average of 64.60%. While earnings contracted in 2025, that followed EPS growth of nearly 582% in 2024 and roughly 66% in 2023.
Analysts expect Hims & Hers Health's earnings to grow about 79.31% next year, from $0.29 per share to $0.52 per share.
HIMS Receives Analyst Upgrades as Wall Street Turns Bullish on Telehealth
Following the Novo Nordisk deal, Bank of America Securities upgraded HIMS to Neutral from Underperform and raised its price target to $23 from $12.50.
Notably, the firm's prior target excluded contributions from GLP-1 revenue, underscoring that the Novo Nordisk agreement is being viewed as a significant bullish catalyst on Wall Street.
Overall, the stock carries a consensus Hold rating based on 17 analysts currently covering the name. The average one-year price target implies more than 32% potential upside.
Current short interest of 43.24% of shares outstanding is worth monitoring; that figure—equating to about $1.32 billion in shares—is substantially lower than the $4.27 billion that were shorted last July. That downtrend has continued, and it would not be surprising if institutional buyers once again outnumbered sellers in the quarters ahead as the Novo Nordisk deal helps bolster Hims & Hers' top-line growth.
Circle May Be the Biggest Winner of America's Stablecoin Shift
Written by Chris Markoch. Date Posted: 3/22/2026.
Key Points
- Circle’s post-IPO volatility has mirrored shifting expectations for stablecoin regulation and reserve-income economics.
- The GENIUS Act created a federal framework for payment stablecoins that appears to favor regulated issuers such as Circle.
- USDC’s scale is growing, but Circle’s outlook still hinges on rates, distribution economics, and how stablecoin usage evolves.
- Special Report: Elon's "Hidden" Company
Circle Internet Group (NYSE: CRCL) went public on June 5, 2025. The stock was priced at $31 per share, nearly tripled on its first trading day, and climbed to nearly $299 by June 23.
After that run, things got rough for investors who chased the pop. By the end of February 2026, the stock had fallen to around $50. That's a heavy loss for anyone who bought near the top.
Why the Fed's new 24/7 banking system is a trap (Ad)
The Federal Reserve is selling banks their new FedNow system with one major promise: transfers will happen instantly, 24/7/365 with no more weekend or holiday delays—but when your money moves instantly through a centralized government hub, it can also be frozen instantly by automated algorithms inside the Fed's new network. Imagine it's 6:00 p.m. on a Friday when your account is instantly locked by a faceless government computer in Washington because an algorithm flagged a recent purchase or donation as suspicious, cutting you off from your own money until Monday morning or later with no way to pay for anything.
Get the 4 steps to Fed-proof your savings nowStill, Circle has emerged as a market winner at a time when winners have been hard to find. The reason is how the regulatory architecture of American finance has been quietly redrawn—and Circle sits at the center of that change.
This is the story of a piece of Congressional legislation, the GENIUS Act, that may have lived up to its name.
Circle Internet Group Is Not a Traditional Finance Stock
Before getting into the GENIUS Act, it's important to understand Circle's business, which differs from most other finance stocks. The fintech company issues digital dollars—stablecoins called USDC—that move on public blockchains. Every USDC token is backed one-for-one by cash and short-term U.S. Treasury bills. The reserve fund is managed by BlackRock (NYSE: BLK).
Users can redeem USDC for dollars at any time. What makes it different from a bank account is the payment rail: blockchain settlement lets transactions clear 24 hours a day, 365 days a year. There are no correspondent banks, no cut-off times, and no three-day ACH delays.
Circle also issues EURC, a euro-backed equivalent, but USDC is the product that matters for this article. As of this writing, more than $75 billion of USDC is in circulation. The company has processed over $6 trillion in adjusted transaction volume across more than one billion transactions.
How the GENIUS Act Changed Everything
The conventional narrative in crypto circles was that the GENIUS Act, passed in the summer of 2025, would be broadly bullish: regulatory clarity would lead to institutional adoption and higher prices across the board. The reality was more surgical. The GENIUS Act defined what a stablecoin is, who can issue one, and under what conditions. It required 100% reserves in high-quality liquid assets, mandated regular disclosures, and established federal oversight. It also drew a line that decentralized assets like Bitcoin cannot cross: an identifiable, regulated issuer.
The practical effect was to formalize a two-tier digital money system. Compliant, reserve-backed stablecoins—led by USDC—became legally recognized payment instruments. Everything else, including Bitcoin (BTC), remained in a separate, murkier category. By January 2026, President Trump had signed an executive order banning federal agencies from issuing or endorsing a central bank digital currency. Congress moved to make that prohibition permanent through at least 2030. The government didn't just step aside from building a digital dollar; it banned itself from doing so—and handed the lane to Circle.
Bitcoin's Quiet Problem
This is where the analysis gets uncomfortable for Bitcoin holders. The bull case for Bitcoin has rested on several pillars: digital scarcity, decentralization, censorship resistance, and, crucially, its role as a global 24/7 payment rail that bypasses traditional banking infrastructure. That last pillar is under pressure in a way not yet fully priced into the market.
The data is striking. Since the GENIUS Act passed, stablecoins have accounted for 93.2% of all transaction volume on public blockchains. Monthly stablecoin transaction counts have reached record highs, while Bitcoin transaction counts have declined more than 20% over the same period. If someone wants to move dollars across borders instantly without a bank, they no longer need Bitcoin. USDC does the job faster, cheaper, and with a stable value.
This is not a call for Bitcoin's demise: the digital scarcity and store-of-value arguments remain, and nation-state adoption as a reserve asset is a different category entirely. But losing even one leg of the investment thesis creates real pressure. Options markets pricing equal odds of $70,000 and $130,000 for Bitcoin by June 2026 suggest the market has no consensus on the asset's value in this new environment.
What the Bull Case Actually Requires
The case for CRCL at current prices requires several things to be true simultaneously:
- USDC circulation continues to grow at roughly a 40% annual rate.
- Federal Reserve interest rates remain elevated long enough for reserve income to compound.
- The Circle Payment Network generates meaningful transaction-fee revenue to cushion against eventual rate cuts.
- The Coinbase revenue-sharing arrangement doesn't become more punitive as the relationship evolves.
What Circle has built is historically rare: private financial infrastructure the U.S. government has explicitly chosen not to compete with, embedded in the payment rails of Visa (NYSE: V), Mastercard (NYSE: MA), and Intuit (NASDAQ: INTU), with BlackRock managing reserves and BNY Mellon holding custody. The moat is institutional trust, regulatory alignment, and network effects—not the technology itself, which any well-capitalized entity could replicate. The question is not whether Circle survives; it's whether the market has already priced in all the good news.
The chart suggests it probably has. The investment thesis says it possibly has not. That tension is exactly what makes Circle worth watching.
to bring you the latest market-moving news.
This email message is a paid advertisement provided by NXT Wave Research, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 N Reid Place #620, Sioux Falls, S.D. 57103. United States..
0 Response to "Elon’s Private AI Empire: The Backdoor Under $100"
Post a Comment